{"groups":[{"description":"2mg Pomolidomide per day per Cycle (Cycle = 28 days)","id":"FG000","title":"Cohort 2"},{"description":"1mg Pomolidomide per day per Cycle (Cycle = 28 days)","id":"FG001","title":"Cohort 3"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"6"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"6"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Six patients were screen failures; did not meet inclusion criteria. Original study design included Arms with assignment to increasing dose escalation including 3 and 4mg Pomolidomide Arms/Cohorts; however, safety concerns early on regarding Dose Limiting Toxicities for 2mg Cohort compelled omitting the 3 and 4mg Arms/Cohorts.","recruitmentDetails":"Patient Eligibility:Waldenstrom relapsed,\\>/18 - years old,ECOG \\<\\~2,Labs NCS,no prior cancers,females not preganant,\\~1\\> line(s) prior therapy, no therapy in 4 weeks. Excluded:pregnant, breast-feeding, serious diagnosis,chemotherapy reaction,prior pomalidomide,HIV/ Hepatitis A-C +,concurrent chemotherapy,grade\\~\\>2 neuropathy,andANC count \\<\\~1000K/ul."}